BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30128801)

  • 1. Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin.
    Avendano R; Romero J; Lupercio F; Diaz JC; Quispe R; Golive A; Natale A; Garcia MJ; Krumerman AK; Di Biase L
    J Interv Card Electrophysiol; 2019 Jan; 54(1):73-80. PubMed ID: 30128801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Yu HT; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
    J Cardiol; 2019 Jun; 73(6):515-521. PubMed ID: 30770140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
    Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis.
    Bai Y; Guo SD; Deng H; Shantsila A; Fauchier L; Ma CS; Lip GYH
    Age Ageing; 2018 Jan; 47(1):9-17. PubMed ID: 28985259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation.
    Lupercio F; Romero J; Peltzer B; Maraboto C; Briceno D; Villablanca P; Ferrick K; Gross JN; Kim S; Fisher J; Di Biase L; Krumerman A
    Am J Med; 2018 May; 131(5):573.e1-573.e8. PubMed ID: 29274758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials.
    Patti G; Di Gioia G; Cavallari I; Nenna A
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 28029216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
    Adam SS; McDuffie JR; Ortel TL; Williams JW
    Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis.
    Liao XZ; Fu YH; Ma JY; Zhu WG; Yuan P
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):391-399. PubMed ID: 32206988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.
    Frederiksen AS; Albertsen AE; Christesen AMS; Vinter N; Frost L; Møller DS
    Europace; 2018 Jul; 20(7):1078-1085. PubMed ID: 28655151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis.
    Zhou Y; He W; Zhou Y; Zhu W
    J Thromb Thrombolysis; 2020 Aug; 50(2):311-317. PubMed ID: 31792707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis.
    Lin L; Lim WS; Zhou HJ; Khoo AL; Tan KT; Chew AP; Foo D; Chin JJ; Lim BP
    J Am Med Dir Assoc; 2015 Dec; 16(12):1103.e1-19. PubMed ID: 26527225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.
    Telles-Garcia N; Dahal K; Kocherla C; Lip GYH; Reddy P; Dominic P
    Int J Cardiol; 2018 Oct; 268():143-148. PubMed ID: 30041779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review.
    Fu Y; Zhu W; Zhou Y; Chen H; Yan L; He W
    Am J Cardiovasc Drugs; 2020 Apr; 20(2):139-147. PubMed ID: 31485852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.